Quest Diagnostics lifts annual forecast on strong testing demand

• Q2 revenue hit $3.04 billion, beating estimates of $2.97 billion, with adjusted profit of $3.12 per share; diagnostic information services revenue grew 10.3% to $2.98 billion
• Requisition volumes increased 13.1%, including 13.0% organic growth, with double-digit growth in advanced diagnostics like Alzheimer's blood tests and cardiometabolic testing
• Full-year 2026 revenue forecast raised to $11.95-$12.05 billion from prior $11.78-$11.90 billion guidance, above analyst estimates of $11.85 billion

Quest Diagnostics Raises 2026 Forecast on Strong Testing Demand

Quest Diagnostics reported better-than-expected Q2 results on Thursday, July 23, prompting the company to raise its full-year profit outlook amid robust demand for diagnostic testing services.

Key Financial Results:

• Q2 revenue reached $3.04 billion, surpassing analyst estimates of $2.97 billion
• Adjusted earnings per share of $3.12 beat expectations
• Diagnostic information services revenue, the company's largest segment, grew 10.3% year-over-year to $2.98 billion
• Requisition volumes increased 13.1%, including 13.0% organic volume growth

Guidance Update:

• Full-year 2026 revenue forecast raised to $11.95-$12.05 billion, up from previous guidance of $11.78-$11.90 billion and above analyst consensus of $11.85 billion
• Adjusted profit expected at $11.05-$11.25 per share for 2026

Performance Drivers:

Quest cited strong demand across physician, hospital, and consumer channels. The company reported double-digit growth in advanced diagnostics businesses, including Alzheimer's disease blood tests, advanced cardiometabolic tests, and liver fibrosis testing.

Market Context:

Barclays analysts noted results were "well above what was widely expected." Industry peer Labcorp similarly posted above-expectation quarterly results, indicating sustained demand across the diagnostic testing sector.

Implications:

The robust performance and raised guidance suggest continued momentum in healthcare diagnostics, particularly in advanced testing categories. Strong volume growth across all channels indicates healthy underlying demand fundamentals in the sector, potentially benefiting other laboratory and diagnostic services providers.